COVID-19’s Damage To Gene Therapy Development May Last Years

 
• By Derrick Gingery
  
Peter Marks at FDLI Regenerative Medicine conference screenshot
CBER Director Peter Marks said the pandemic also exasperated the backlog of pending INTERACT meetings. • Source: screenshot
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies